Arcadia Biosciences, Inc. · NASDAQ:RKDA
Arcadia Biosciences — Q1 2017 Earnings Presentation
10 slides from Arcadia Biosciences's earnings presentation, May 10, 2017
Slide 1: First Quarter 2017 Financial Results and Business Highlights
First Quarter 2017 Financial Results and Business Highlights May 10, 2017
Slide 2: Forward-looking statements
Forward-looking statements “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This presentation c ontains forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success;; the
Slide 3: Recent changes are producing improved results
Recent changes are producing improved results Revenue increased by 19% compared to Q1 last year Operating expenses down by 14% Net loss from operations significantly improved by 20% Streamlined organization is focusing on key products 3
Slide 4: Ingredients business making great progress
Ingredients business making great progress GLA safflower oil • Sales revenue on track for growth in 2017 • Obtained FDA GRAS (generally recognized as safe) notification for use in medical foods and nutritional beverages • Successfully c ompleted FDA food additive review process for use in dog food A
Slide 5: Ag Productivity traits continue to advance
Ag Productivity traits continue to advance HB4 stress-tolerant soybeans • Argentina field trials of HB4 trait in commercial varieties are nearing harvest • Regulatory work for Europe and other countries continues with our Verdeca JV partner, Bioceres Corn yield and stress traits • 2016 data was rev
Slide 6: Progress in our grants and contract research projects
Progress in our grants and contract research projects USAID-sponsored trials • NUE Nerica rice lead events show consistently good performance in 10 trials in 4 countries: Columbia, Ghana, Uganda and Nigeria • Field trials of NUE/WUE/ST stacked traits in rice initiated in Columbia • Field trials of
Slide 7: Revenue
Revenue First Quarter $ Favorable/ % Favorable/ 2017 2016 (Unfavorable) (Unfavorable) Product revenue 205 255 (50) (20)% License revenue 106 152 (46) (30)% Contract research and government grants 707 445 262 59% Total revenues 1,018 852 166 19% $ in thousands;; Unaudited Q1#2017#Revenue Q1#2016#Reve
Slide 8: Operating expenses
Operating expenses First Quarter $ Favorable/ % Favorable/ 2017 2016 (Unfavorable) (Unfavorable) Cost of product revenues 106 147 41 28% R&D expense 1,823 2,202 379 17% SG&A expense 3,052 3,436 384 11% Total operating expenses 4,981 5,785 804 14% $ in thousands;; Unaudited Q1#2016#Expenses Q1#2017#E
Slide 9: Key financial results
Key financial results First Quarter $ Favorable/ % Favorable/ 2017 2016 (Unfavorable) (Unfavorable) Total revenues 1,018 852 166 19% Cost of product revenues 106 147 41 28% R&D expense 1,823 2,202 379 17% SG&A expense 3,052 3,436 384 11% Loss from operations (3,963) (4,933) 970 20% Net loss and net
Slide 10: Thank you!
®D Arcadia BIOS CIEN CE S&S Thank you!